Bioreactors Market Size By Product Type (Single-use, Reusable), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy), By Usage (Developmental, Pre-clinical & Clinical, Commercial Production), By End-use (R&D Organizations, Biopharma Manufacturers, Contract Manufacturing Organizations [CMOs]), Industry Analysis, Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: Mar 2021  |  Report ID: GMI141  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 205   |   Base Year: 2020

Summary Table of Contents Industry Coverage Methodology

Industry trends

Bioreactors Market size was valued at over USD 5.4 billion in 2020 and is expected to witness a 16.6% CAGR from 2021 to 2027. Incidence of COVID-19 pandemic has considerably driven the demand for preventive vaccines and effective treatment therapeutics. In order to cater to growing demand for drugs, several pharmaceutical manufacturers have extended their production capacities, thereby, boosting the bioreactors sales during the pandemic. Additionally, rising R&D activities for vaccine development across the globe have created the potential for clinical-stage bioreactors.

Bioreactors Market

Get more details on this report - Request Free Sample PDF

Bioreactors are used as apparatus for growth cultivation of organisms such as animal cells, mammalian cells, yeast cells and bacteria under controlled conditions. They are used in industrial processes to produce pharmaceuticals including monoclonal antibodies and vaccines among other products. Broad applications in commercial production of biological products are expanding their adoption in healthcare industry.

Growing pervasiveness of various chronic disorders such as cancer, cardiovascular diseases and diabetes will fuel the therapeutics production, thus stimulating bioreactors market growth. For instance, increasing developmental activities to provide effective cancer treatment with novel therapies is predicted to augment the demand for bioreactors. Therefore, the use of advanced bioprocessing technologies during therapeutics development for various diseases is anticipated to provide unprecedented growth opportunities to the industry.

Advancements in equipment design to optimize bioprocessing during drug development will stimulate product supply

Advancements in bioreactors’ features and processing will enhance the bioreactors market expansion. Manufacturers are continuously focusing on development of equipment to offer increased control, ease in scaling up to process large volume and simplification of in-vivo systems.  Additionally, development in design allowing cost-effectiveness at large-scale manufacturing further impels the product demand in the market. Moreover, growing acceptance of single-use technologies owing to their benefits including efficiency in air and gas transfer, proper mixing of cells, and flexible operating conditions to maximize final outcomes will positively impact the business growth. However, concerns associated with extractables impacting the quality of products and human health will moderately affect the industry growth during the forecast period.

Improved scalability with high volume capacity will strengthen the growth potential of reusable bioreactors in the industry

Reusable bioreactors market dominated more than 75% of revenue share in 2020 led by their higher usage in bulk product manufacturing. High volume capacity and increased scalability drive the product demand. During commercial production, the use of single-use bioreactors results in increased product costs due to repetitive purchases and installations. This will lead to a preference for reusable systems in these facilities. Furthermore, reusable bioreactors are less susceptible to punctures.

Development of advanced bioreactors offering less shear damage to cells will result in the exponential market demand

Mammalian cells segment in the bioreactors market accounted for USD 4 billion in 2020. Wide usage of mammalian cells in production of therapeutic proteins and viral vaccines among other biopharmaceuticals will augment the demand for bioreactors. These cells are used in generating tissue analogues for regenerative medicines. The sensitivity and exposure to shear damage of these cells have offered considerable growth opportunities to advanced bioreactors employing low agitation rates to obtain high throughput. Thus, with wide application of mammalian cells in biopharmaceutical manufacturing, the segment will foresee robust growth in future.

Incidence of COVID-19 augmenting the demand for vaccines will boost the bioreactors supply in the pharmaceutical industry

Bioreactors Market Size

Get more details on this report - Request Free Sample PDF

Vaccines segment held for over 47% of the bioreactors market share in 2020. Extensive R&D activities for vaccine development will provide demand for bioreactors. Incidence of severe infectious diseases has spurred vaccine development activities in past few years.

Incidence of COVID-19 further added in vaccines R&D across the globe. For instance, in November 2020, the Government of India announced the third stimulus package for COVID-19 vaccine development. Government support, influencing vaccine development will augment the bioreactors demand. Increasing number of vaccine candidates in pre-clinical and clinical phases for several other infectious diseases will propel the segment growth during the forecast period.

Increasing bioreactors demand for clinical studies with a focus of biopharma manufacturers on innovation will foster the market value

Developmental, pre-clinical & clinical segment in the bioreactors market is projected to expand at 20.9% growth rate by 2027. Increase in number of pre-clinical and clinical stage studies in development of various therapeutic drugs for rare and chronic diseases has created demand for small-scale bioreactors.

Continuous focus of pharmaceutical manufacturers on product innovation with increasing R&D expenditure also boosts the bioreactors market revenue. Moreover, the product demand will increase as it assists in improving the overall manufacturing process and providing high-quality products, thereby minimizing cost associated with further failures. Thus, increasing focus on innovation will expand the market in the foreseeable future.

Benefits in manufacturing of complex molecules will drive demand for bioreactors in biopharmaceutical manufacturing

Biopharma manufacturers segment accounted for over 40% of the bioreactors market share in 2020. Growing usage of high-end technologies to ease complex manufacturing will stimulate the demand for bioreactors in the coming years. Applications of bioreactors in manufacturing and development of complex molecules including proteins and nucleic acids also impels the segment revenue.

Increasing biopharmaceuticals manufacturing capacities in developing nations has offered significant demand for bioreactors market. Need for bioreactors supporting modern, high-cell-density and intensified processes requiring high oxygen transfer and excellent carbon dioxide removal favours product adoption, thereby propelling the segment value over the coming years.

Increasing R&D activities for development of novel biologics will stimulate the acceptance of bioreactors in North America region

North America Bioreactors Market

Get more details on this report - Request Free Sample PDF

North America bioreactors market size was over USD 2 billion in 2020 on account of the presence of leading players, focusing on product innovation, rising R&D expenditure and growing prevalence of chronic diseases. Additionally, increase in number of academic institutes and expanding research & development facilities further creates significant demand for bioreactors in the region.

Government funding to fuel the R&D for development of vaccines with recent incidence of COVID-19 has enhanced the regional expansion. Thus, extensive research and development activities to develop novel biological drugs will drive the growth across North America region in the coming years.

Prominent industry players are focusing on strategic collaborations and product launch that will foster their business growth potential

Some of the leading companies operating in the bioreactors market include Merck Group, Cytiva, Getinge (Applikon Biotechnology), Eppendorf AG, Sartorius Group and Thermo Fisher Scientific. These industry leaders are adopting various inorganic growth strategies to obtain a competitive advantage and strengthen their market position.

Some of the recent industry developments:

  • In March 2020, Danaher announced the complete acquisition of biopharma business of General Electric Life Sciences, called CYTIVA. This strategy helped the company in setting up footprint in the market.
  • In March 2020, Sartorius launched BIOSTAT STR Generation 3 single-use bioreactor with BIOBRAIN making biopharmaceutical development and production simpler, safer and faster. This launch helped the company to increase its business growth in the market.
  • In February 2020, Eppendorf launched SciVario twin, a bioreactor controller system for small bench-scale bioreactors. The launch of next generation bio controller enabled remote monitoring of cell culture processes, thereby enhancing its product portfolio.

The bioreactors market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2021 for the following segments:

Market, By Product Type

  • Single-use
  • Reusable

Market, By Cell

  • Mammalian cells
  • Bacterial cells
  • Yeast cells
  • Others

Market, By Molecule

  • Monoclonal antibodies
  • Vaccines
  • Recombinant proteins
  • Stem cells
  • Gene therapy
  • Others

Market, By Usage

  • Developmental, Pre-clinical & Clinical
  • Commercial Production

Market, By End-use

  • Research & Development (R&D) Organizations
  • Biopharmaceutical Manufacturers
  • Contract Manufacturing Organizations (CMO)

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Netherlands
    • Denmark
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Singapore
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
    • UAE


Frequently Asked Questions (FAQ) :

The bioreactors industry size reached USD 5.4 billion in 2020 and will observe a 16.6% CAGR through 2027 owing to the increasing demand for preventive vaccines and effective treatment therapeutics in the present COVID-19 pandemic.
Reusable bioreactors contributed to 75% of the bioreactors market share in 2020 and will witness higher demand in bulk product manufacturing.
The bioreactors market size from the vaccines segment was valued at 47% of the revenue share in 2020 and will rise with the surge in the number of R&D activities for vaccine development.
Biopharma manufacturers accounted for 40% of the total market share in 2020 and will register significant demand through 2027 due to the higher adoption of high-end technologies.
The bioreactors market size for the North America region exceeded USD 2 billion in 2020 and will grow owing to the growing prevalence of chronic diseases and the strong presence of leading industry players across the region.

Premium Report Details

  • Published Date: Mar 2021
  • Pages: 205
  • Tables: 299
  • Charts / Figures: 19
  • Companies covered: 15
  • Countries covered: 19

Get a report that explains COVID-19 impact on this market

Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X